文献速递抗栓抗凝管理特殊人群用药

SARS-CoV-2疫苗接种后静脉血栓栓塞风险:全基因组关联研究与人群观察性研究证据

Risk of venous thromboembolism after SARS-CoV-2 vaccination-Evidence from genome-wide association study and population-based observational study.
PubMed 文献 · Br J Clin Pharmacol · 2026-05-28

观察性登记研究显示血栓形成倾向诊断者接种后42天内静脉血栓栓塞风险升高约五倍(OR 5.06)。

要点

  • 凝血因子II rs1799963与疫苗接种后静脉血栓栓塞显著相关(OR 2.4)。
  • 凝血因子V rs6025与静脉血栓栓塞显著相关(OR 1.8)。
  • 血栓形成倾向诊断者接种后42天内静脉血栓栓塞风险升高约五倍。

核心结论

  • 凝血因子II和V基因中特征明确的遗传变异与SARS-CoV-2免疫后血栓栓塞相关。

研究设计与样本

  • 观察性登记研究基于瑞典普通人群,比较有/无血栓形成倾向诊断者接种后静脉血栓栓塞风险。

主要发现

  • 候选基因分析和全基因组分析中无遗传标记通过显著性阈值。
  • 登记研究中,有血栓形成倾向诊断者接种后42天内静脉血栓栓塞风险升高,调整混杂因素后OR 5.06(95%CI 3.98-6.44)。

局限性

  • 需进一步研究阐明凝血因子II和V变异在疫苗相关血栓栓塞事件中的潜在作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS-CoV-2 vaccines. METHODS: We conducted a genome-wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS-CoV-2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish Medical Products Agency. Two hundred one cases (43% women, 91% Swedish) were compared with 4891 Swedish population controls. Analyses were performed on two candidate variants in coagulation factor II (rs1799963) and coagulation factor V (rs6025), on 14 prespecified candidate genes and across the whole genome. To support the findings, we conducted an observational register study of the Swedish general population with/without a diagnosis of thrombophilia and the risks of venous thromboembolism after SARS-CoV-2 vaccination. RESULTS: In the GWAS, the main findings were that the candidate variants of coagulation factors II rs1799963 and V rs6025 were significantly associated with venous thromboembolism (odds ratio [OR] 2.4 [95% confidence interval (CI) 1.2-4.8], p = .015 and OR 1.8 [95% CI 1.3-2.6], p = .0022). No genetic marker passed the significance threshold in the candidate gene analysis or the full genome-wide analysis. In the register study, people with a thrombophilia diagnosis had a five-fold elevated risk of venous thromboembolism within 42 days after vaccination, adjusted for potential confounders, OR 5.06 [95% CI 3.98-6.44]. CONCLUSION: Well-characterized genetic variants in the genes of coagulation factors II and V were associated with thromboembolism after SARS-CoV-2 immunization. Further research is recommended to elucidate their potential role in vaccine-related thromboembolic events.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Attelind S, Eriksson N, Cavalli M, et al. Risk of venous thromboembolism after SARS-CoV-2 vaccination-Evidence from genome-wide association study and population-based observational study. Br J Clin Pharmacol. 2026. PMID: 42204965. doi:10.1002/bcp.70614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。